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Microarray and bioinformatic detection of novel and estab-
lished genes expressed in experimental anti-Thy1 nephritis.
Background. Microarray technology is a powerful tool that
can probe the molecular pathogenesis of renal injury. In this
present study microarray analysis was used to monitor serial
changes in the renal transcriptome of a rat model of mesangial
proliferative glomerulonephritis. Administration of anti-Thy1
antibody results in phases of acute mesangial injury (day 2),
cell proliferation (day 5), matrix expansion (days 5 and 7), and
subsequent healing (day 14).
Methods. Using Affymetrix (RAE230A) microarrays cou-
pled with sequential primary biologic function-focused and sec-
ondary “baited” global cluster analysis, a cohort of established
and putative novel modulators of mesangial cell turnover was
identified.
Results. Cluster analysis of proliferative genes identified a
number of gene expression profiles. The most striking pat-
tern was increased gene expression at day 5, a cluster that
included platelet-derived growth factor (PDGF), cyclins and
transforming growth factor-b (TGF-b). The gene expression
patterns identified by primary focused cluster analysis were
used as bioinformatic bait and resulted in the identification of
novel families of genes such as the S100 family. The expres-
sion of established and novel genes was confirmed using re-
verse transcription-polymerase chain reaction (RT-PCR). Next,
in vivo gene expression was compared to PDGF-stimulated
mesangial cells in vitro revealing similar patterns of dysregu-
lation.
Conclusion. Transcriptomic analysis defined both known and
novel molecules involved in mesangial cell proliferation in vitro
and in vivo and defined a panel of molecules that are poten-
tial contributors to mesangial cell dysfunction in glomerular
disease.
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Mesangial cell proliferation is a key pathogenic factor
in a number of major diseases including IgA nephropathy
(IgAN) and lupus nephritis [1, 2]. Proliferating mesangial
cells undergo a phenotypic switch to an “activated” phe-
notype and release a variety of mediators with potent
local paracrine and autocrine actions that perturb
glomerular structure and filtration. In some cases mesan-
gial cell proliferation is associated with dysregulation of
extracellular matrix metabolism and mesangial matrix ex-
pansion [2]. The molecular triggers for mesangial cell pro-
liferation and the intracellular signaling responses that
disturb mesangial cell activation state and function are
still being appreciated. While important roles for growth
factors such as platelet-derived growth factor (PDGF)
have been defined, it is likely that these represent but a
fraction of a series of complex and interrelated molec-
ular pathways that together dictate the final glomerular
phenotype.
Microarray technology permits large scale profiling of
gene expression and is a powerful tool with which to
probe the molecular pathogenesis of renal injury. In this
study, microarray analysis was used to probe the molec-
ular mechanisms that underpin mesangial cell prolifer-
ation. This was done by the exploration of in vivo and
in vitro models of mesangial cell proliferation. Initially,
microarray analysis was used to monitor serial changes
in the renal transcriptome during the evolution of anti-
Thy1 nephritis model of mesangial proliferative glomeru-
lonephritis. In this model, administration of anti-Thy1
antibody is associated with phases of acute mesangial
injury, cell proliferation, matrix expansion, and subse-
quent healing with cell proliferation peaking at 5 days
post-anti-Thy1 antibody. Using a bioinformatic approach
that incorporates sequential primary biologic function–
focused and secondary “baited” global cluster analysis,
established and putative novel modulators of mesangial
cell proliferation were identified. However, to further
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explore the role of these modulators on mesangial cell
proliferation, the expression of a cohort of these genes
was studied in an in vitro model of mesangial cell prolif-
eration. Here, PDGF stimulation resulted mesangial cell
proliferation and these cells were subsequently treated
with lipoxin, an inhibitor of mesangial cell proliferation.
Simply, using microarray analysis, a cohort of estab-
lished and novel modulators of mesangial cell prolifera-
tion was identified in an in vivo model of mesangial cell
proliferation. The expression of these genes was then fol-
lowed in an in vitro model of mesangial cell prolifera-
tion. By this method it was possible to define a panel of
molecules that are potential contributors to mesangial
cell dysfunction in glomerular disease.
METHODS
Rodent model of anti-Thy1 mesangial proliferative
glomerulonephritis in vivo
Wistar rats weighing 180 to 200 g were kept under stan-
dard conditions and were randomly allocated to either
control or experimental groups. Experimental prolifer-
ative nephritis (anti-Thy1 nephritis) was induced by a
single intravenous injection of goat anti-Thy1 antibody
at a dose of 0.3 mL/100 g. Age-matched controls were
injected with the same volume of isotonic saline. Anti-
Thy1–treated animals were sacrificed at days 0, 2, 5, 7,
and 14 following injection. Cortical regions of the left kid-
ney from each time point were collected, and glomeruli
were isolated using the sieving method while right kid-
neys were collected for histologic analysis.
Human mesangial cell culture in vitro
Human mesangial cells were isolated from a nephrec-
tomy sample obtained from the Mater Misercordiae Uni-
versity Hospital in accordance with institutional, ethical
guidelines. As previously described [3], a sample of cor-
tex was isolated and differentially sieved in order to ex-
tract the glomeruli, which were subsequently grown on
collagen-coated plates. Cells were cultured in RPMI 1640
supplemented with 10% fetal calf serum (FCS), penicillin
(100 U/mL), and streptomycin (100 lg/mL), which was se-
lective for mesangial cell growth. These cells retained the
phenotypic characteristics of mesangial cells, including
stellate morphology, positive staining for vimentin and
alpha-smooth muscle actin (a-SMA) and negative stain-
ing for zonula occludens-l antigen (ZO-1) and occluding
[1]. Human mesangial cells were serum restricted (RPMI
1640 supplemented with 0.2% FCS) for 48 hours prior to
serum starving (RPMI 1640 supplemented with 0% FCS)
for a further 1 hour before stimulating. Cells were subse-
quently treated with PDGF (10 ng/mL) in 0% FCS RPMI
1640 for 24 hours.
Oligonucleotide microarray analysis
RNA isolation, cDNA synthesis, in vitro transcription,
and microarray analysis were performed as previously
reported [4]. Briefly, total RNA was isolated from whole
kidneys at baseline and 2, 5, 7, and 14 days postinjection of
anti-Thy1 antibody and from mesangial cells in vitro us-
ing RNeasy Mini Column (Qiagen, Valencia, CA, USA).
cDNA was synthesized from total RNA using Superscript
Choice Kit (Invitrogen, Carlsbad, CA, USA). Biotin-
labeled cRNA prepared from template cDNAs was frag-
mented and hybridized to the Affymetrix RAE230A
arrays as per Affymetrix protocol (Affymetrix, Santa
Clara, CA, USA). Arrays were then washed and fluores-
cently labeled prior to scanning with a confocal scanner
(Affymetrix). All in vivo time points were microarrayed
as experimental duplicates.
With regard to the mesangial cell in vitro experiment,
RNA from three independent experiments was pooled
after isolation using lysis buffer guanidine isothiocyanate
(RLT) and b-mercaptoethanol in accordance with the
Qiagen minicolumn preparation (Qiagen, Valencia, CA,
USA). Complementary DNA (cDNA) synthesis, in vitro
transcription, and microarray analysis were carried out
as has been described. As before, all in vitro time points
were microarrayed as experimental duplicates.
Bioinformatic and data analysis
Image files were obtained through Affymetrix
GeneChip software (MAS5). Subsequently, robust mul-
tichip analysis (RMA) was performed [5, 6]. RMA is
an R-based technique that analyses directly from the
Affymetrix microarray ∗.cel image ﬁle and comprises
three steps: background adjustment, quantile normaliza-
tion, and summarization. In order to use a Microsoft
Windows operating system RMAexpress was used. This
package is a stand-alone graphical user interfaces (GUI)
program specifically designed to operate on Microsoft
Windows and exclusively performs RMA [5, 6].
For each in vivo time point, an average RMA value
was computed for duplicate microarrays and to ensure
the average was statistically representative a t test and
P value were generated. Only those genes with a P value
of ≤0.01 were included in subsequent bioinformatic anal-
ysis [7, 8]. Thereafter, expression data for each time point
were compared to control and a signal log ratio of 0.6 or
greater (equivalent to a fold change in expression of 1.5
or greater) was taken to identify significant differential
regulation.
Using normalized RMA values, cluster analysis was
performed by the program of Eisen et al [9] entitled,
“Unsupervised Average Linkage Hierarchical Cluster
Analysis.” Cluster analysis groups together genes with
comparable patterns of expression by employing math-
ematical methods of similarity organize patterns of
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expression [9]. Initially, all the genes under study are as-
sessed and the two closest genes are joined creating the
first node. Subsequent nodes are determined and added
by the pair-wise joining of genes, based on the distance
between them, culminating in all genes belong to the one
node. To ensure tight cluster analysis and reduce the back-
ground noise that accompanies microarray experiments,
the 12,488 genes of the Affymetrix mu74av2 chip were
filtered to remove genes with very low expression at all
time points [10, 11]. An initial cluster analysis of each in-
dividual array and the average array for each time point
were performed to ensure that each time point was suffi-
ciently similar in expression profiles to permit the use of
average values thereafter.
A list of 390 mRNA transcripts that encode proteins
involved in cell growth and proliferation but not involved
in apoptosis or oncogenesis was curated via the publicly
available Onto-Compare and Gene-Ontology databases
[12, 13]. A complete list of these genes is available from
the authors and is displayed on the Conway Institute Web
site (http://www.ucd.ie/conway/).
Reverse transcription (RT) and real-time polymerase
chain reaction (PCR)
Total RNA was extracted from glomeruli isolated by
differential sieving from both control rats (N = 5) and
rats with anti-Thy 1 nephritis (N = 5) (day 5) using the SV
Total RNA Isolation Kit (Promega, Madison, WI, USA)
and according to the manufacturer’s protocol. The RNA
was eluted with 50 lL of RNase-free water. All RNA was
quantified by spectrophotometer and the optical density
260/280 nm ratios were determined. RT was performed
in a one-step protocol using the iScriptTMcDNA Synthe-
sis Kit (Bio-Rad, Hercules, CA, USA) according to the
manufacturer’s protocols. Reactions were incubated at
25◦C for 5 minutes, 42◦C for 30 minutes, 85◦C for 5 min-
utes, and cooled at 4◦C in a Thermocycler (Eppendorf,
Hamburg, Germany).
Primers were designed by softwarePCR primers
were designed using Primer3 software [14] and oligonu-
cleotides were synthesized by Sigma Genosys (Sigma-
Genosys Ltd, Pittsburgh, PA, USA). The following
sequence of oligonucleotide primers (300 nmol) were
used: (1) S100A10, forward primer 5′-ttcaaaatgccatcc
caaat-3′; reverse primer 5′-ccccgccactagtgatagaa-3′; (2)
S100A4, forward primer 5′-aggacagacgaagctgcatt-3′;
reverse primer 5′-ctcacagccaacatggaaga-3′; (3) S100A6,
forward primer 5′-cttcattgtcgacgtgtgct-3′; reverse primer
5′-tcagctccttcagctccttc-3′; (4) S100A9, forward primer
5′-aggacctggacacaaaccag-3′; reverse primer 5′-gacttggtt
gggcagatgtt-3′; (5) connective tissue growth factor
(CTGF), forward primer 5′-tagcaagagctgggtgtgtg-3′; re-
verse primer 5′-ttcacttgccacaagctgtc-3′; (6) PDGF-A, for-
ward primer 5′-gagataccccgggagttgat-3′; reverse primer
5′-aaatgaccgtcctggtcttg-3′; (7) transforming growth
factor-b (TGF-b), forward primer 5′-atacgcctgagtggctg
tct-3′; reverse primer 5′-tgggactgatcccattgatt-3′; (8)
vascular endothelial growth factor-C (VEGF-C, for-
ward primer 5′-ccacagtgtcaggcagctaa-3′; reverse primer
5′-actccttgttgggtccacag-3′); (9) enigma, forward primer
5′-gctctctctccctcgacctt-3′; reverse primer 5′-cagagtgaact
ggggctagg-3′; and (10) meosin, forward primer 5′-cttcag
caactcctcccttg-3′; reverse primer: 5′-actttccttccggacatcct-
3′. Real-time PCR analyses were performed using the
Opticon PCR machine (MJ Research, Waltham, MA,
USA). The SYBR Green Master Mix Kit (Bio-Rad) was
used for all reactions with real-time PCR. Briefly, PCR
was performed as 94◦C for 2 minutes followed by 40
cycles of denaturation, annealing, and extension at 94◦C
for 15 seconds, 64◦C for 30 seconds, 72◦C for 45 seconds,
respectively, and final extension at 72◦C for 10 minutes.
PCR reaction for each sample was done in duplicate for
all the product and for the glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) control. Ratios for each
product/GAPDH mRNA were calculated for each
sample and expressed as the mean ± SD.
RESULTS
Global patterns of gene expression during anti-Thy1
nephritis
Administration of anti-Thy1 antibody was associated
with acute mesangial injury followed by cell prolifera-
tion and matrix expansion (Fig. 1A), as previously de-
scribed [15]. When individual and computed average mi-
croarrays were clustered, there was strong alignment to
their respective time point as illustrated in Figure 1B. Of
the 15,923 gene sequences expressed on the Affymetrix
RAE230A oligonucleotide microarray, 5.6% (886 genes),
19.9% (3180 genes), 4.6% (741 genes), and 12.6% (2010
genes) were perturbed at days 2, 5, 7, and 14 follow-
ing anti-Thy1 antibody injection, respectively (Fig. 1C).
Tables 1 and 2 highlight the genes whose mRNA levels
changed most dramatically at days 2, 5, 7, and 14.
Figure 1D summarizes the pattern of change within
major gene families, classified on the basis of known func-
tion. There were two major peaks of gene expression
notable in this study; at day 5, which coincides with maxi-
mal mesangial proliferation and moderate matrix expan-
sion and at day 14 when the histology is dominated by
matrix expansion and reduction in mesangial cell num-
ber due to the early resolution of injury. Among the
functional cohorts of genes changed most markedly at
both time points were proliferative and defense response
genes. Notable also, however, were developmental and
metabolism genes, gene families not classically associated
with nephropathy.
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Fig. 1. Global changes in gene expression in anti-thy1 nephritis. (A) The histologic injury in anti-thy1 nephritis with an initial complement-dependent
mesangiolysis at day 2 followed by mesangial cell proliferation, apoptosis, angiogenesis, and matrix expansion. Mesangial cell proliferation peaks
at day 5 at which time there is the beginning of mesangial matrix expansion. At day 7 there is endothelial cell proliferation and by day 14 there is
increased mesangial matrix and some segmental sclerosis. By day 14 resolution of injury has begun and there is a notable decrease in the number
of mesangial cells. Each time point was assessed in duplicate using RAE230A Affymetrix microarray, which displays 15,923 transcripts. (B) The
hierarchic cluster analysis of individual and the average arrays, as can be seen arrays cluster according to disease time point. (C) The global changes
in gene expression with a signal log ratio (SLR) of ≥ +0.6 defining up-regulation and a SLR ≤ −0.6 defining down-regulation of individual genes.
(D) Changes in gene expression within major functional families as defined by Onto-Express. The full list of genes within each class is available on
the Conway Institute Web site (http://www.ucd.ie/conway/).
Primary biologic function–focused cluster analysis
identifies known and new modulators of cell proliferation
in anti-Thy1 nephritis
Mathematically “tight” clusters of genes following per-
turbation of biologic systems can infer a commonality
of function or regulation [9]. In the present study, the
expression profile of 390 genes previously implicated in
the regulation of cell turnover was first assessed in anti-
Thy1 nephritis using unsupervised hierarchic clustering,
thereby defining the major patterns of expression within
this functional class (primary proliferation-focused clus-
ter analysis). Genes within these major proliferative
clusters were then used as bioinformatic bait to probe
the remainder of the renal transcriptome for other genes
with similar patterns of expression and potential func-
tional or regulatory associations with known modulators
of cell turnover (secondary baited global cluster analysis).
Of the 390 proliferative genes, 47% (182 mRNA tran-
scripts) had a signal log ratio of ≤ −0.5 and ≥ +0.5 at one
or more time points and were considered for primary un-
supervised hierarchic cluster analysis (Fig. 2). The most
striking finding was the dominance of increased gene ex-
pression at day 5 (Fig. 2, primary clusters A to F). Closer
inspection identified three separate patterns: (1) those
genes that were exclusively up-regulated at day 5 (Fig. 2,
primary clusters A, B, and F); (2) genes that are expressed
early, at days 2 and 5, following glomerular injury (Fig. 2,
primary clusters D and E); and (3) genes with a bipha-
sic response that are up-regulated at both days 5 and 14
(Fig. 2, primary cluster C).
Additionally, there was a small cohort of genes per-
turbed at day 14 (Fig. 2, primary clusters G to I). Within
this cohort were a small number of genes that were exclu-
sively up-regulated or down-regulated at day 14 (Fig. 2,
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Table 1. Genes undergoing most striking up-regulation during progressive anti-Thy1 nephritis
Top 10 up-regulated mRNA transcripts SLRa
Accession Title Day 14
BG378249 Butyrophilin-like 2 (MHC class II associated) (BTNL2) 2.8
NM 133298 Glycoprotein (transmembrane) nmb (GPNMB) 2.7
NM 054008 Rgc32 protein (RGC32) 2.6
NM 080906 HIF-1 responsive RTP801 (RTP801) 2.5
NM 013128 Carboxypeptidase E (CPE) 2.5
NM 012551 Early growth response 1 (EGR1) 2.4
AJ249701 RT1 class Ib gene (RT1AW2) 2.4
AA800031 Four and a half LIM domains 2 (FHL2) 2.3
AI170394 Transcribed sequences 2.3
BM390487 Transcribed sequence—moderate similarity to hypothetical protein dkfzp564p1263.1 2.2
Accession Title Day 7
BI282702 Smooth muscle actin-alpha (ACTA2) 2.3
BE128699 Transcribed sequence with strong similarity to collagen VIII alpha1 2.2
BM390487 Transcribed sequence—moderate similarity to hypothetical protein dkfzp564p1263.1 2.1
NM 031549 Transgelin (smooth muscle 22 protein) (TAGLN) 2.0
NM 133298 Glycoprotein (transmembrane) (nmb) (GPNMB) 2.0
AA818342 Transcribed sequences 2.0
AI179399 Collagen, type V, alpha 2 (COL5A2) 1.9
BM388837 Procollagen, type I, alpha 2 (COL1A2) 1.9
AI170394 Transcribed sequences 1.8
AA892854 Transcribed sequences 1.7
Accession Title Day 5
BI282702 Smooth muscle actin-alpha (ACTA2) 4.2
NM 031549 Transgelin (smooth muscle 22 protein) (TAGLN) 4.1
AA818342 Transcribed sequences 4.0
BE128699 Transcribed sequence with strong similarity collagen VIII alpha1 (Rattus norvegicus) 3.8
BI282748 Procollagen, type I, alpha 2 (COL1A2) 3.5
AI169104 Transcribed sequence—strong similarity to platelet factor 4 precursor (PF-4) (CXCL4) 3.5
AI229404 Transcribed sequences 3.3
BI285575 Collagen, type 1, alpha 1 (COL1A1) 3.3
BI275716 Collagen, type III, alpha 1 (COL3A12) 3.2
NM 012889 Vascular cell adhesion molecule 1 (VCAM1) 3.0
Accession Title Day 2
NM 133298 Glycoprotein (transmembrane) (nmb) (GPNMB) 3.4
NM 012580 Heme oxygenase 3.2
BE095824 Transcribed sequence with similarity to small inducible cytokine A3 precursor (CCL3) 3.0
AI170394 Transcribed sequences 2.8
BE098739 Transcribed sequences 2.8
BF418957 Transcribed sequence—similarity to complement protein C1q beta chain precursor 2.8
NM 031348 Ficolin A 2.7
NM 053843 Fc receptor, igg, low affinity III 2.6
BI294706 Weak similarity to immunoglobulin epsilon receptor beta-subunit (FCERI) 2.5
NM 053538 Lysosomal-associated protein transmembrane 5 (LAPTM5) 2.5
aColumns show the mean change in gene expression expressed as signal log ratio (SLR) with a SLR of 0.6, 1.0, 2.0, and 4.0, corresponding to fold changes in gene
expression of 1.5, 2, 4, and 16, respectively.
primary clusters G and H), while a small cluster of genes
demonstrated a biphasic response being down-regulated
at both days 5 and 14. It is noteworthy that there was very
little disturbance of proliferative genes at either day 2 or
7 post-anti-Thy1 antibody injection.
Secondary “baited” global cluster analysis identified
novel molecular associations in anti-Thy1 nephritis
The gene expression patterns identified by primary
proliferation-focused cluster analysis were used as bioin-
formatic bait with which to probe the renal transcrip-
tome for novel modulators of mesangial cell turnover. To
this end, average linkage unsupervised hierarchic analy-
sis was performed on all annotated mRNA transcripts of
the Affymetrix RAE230A microarray with an RMA sig-
nal log ratio of < −0.5 and/or > +0.5 at one or more time
points so as to reduce confounding noise [9–11]. A total
of 2422 mRNA transcripts underwent secondary baited
global cluster analysis. Figure 3 summarizes the pattern
of change within major gene families, classified on the
basis of known function of these genes at day 5 and 14,
correlating to the two major peaks of proliferative gene
expression. Noteworthy is the switch in pattern of gene
family expressed; at day 5, there is a dominance of genes
involved in cytoskeletal and immune response, while by
day 14 it is genes involved in signal transduction and tran-
scription that are more prominent.
Day 5 is characterized by peak mesangial cell prolifer-
ation (Fig. 1A) [15]. Figure 4 focuses on genes that were
exclusively up regulated at day 5 while Figure 5 examines
those genes that had increased expression from day 2,
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Table 2. Genes undergoing most striking down-regulation during progressive Anti-Thy1 nephritis
Top 10 down-regulated mRNA transcripts SLRa
Accession Title Day 14
NM 031055 Matrix metalloproteinase 9 (gelatinase B, 92 kD type IV collagenase) (MMP9) −2.9
U18772 Neuronal pentraxin 1 (NPTX1) −2.8
BI281680 Transcribed sequences −2.3
AI710682 Weak similarity to protein sp:P02593 (R.norvegicus) CALM HUMAN calmodulin −2.2
NM 013122 Insulin-like growth factor binding protein 2 (IGFBP2) −2.1
AI013919 Rattus norvegicus mRNA for cyclin-dependent kinase inhibitor p57 (p57kip2 gene) −2.1
AI599133 Transcribed sequences −2.0
NM 019358 Glycoprotein 38 (GP38) −2.0
D45412 Protein tyrosine phosphatase, receptor type, O (PTPRO) −1.9
AB026903 Decay-accelerating factor (DAF) −1.9
Accession Title Day 7
NM 012531 Catechol-O-methyltransferase (COMT) −2.0
BI287300 Hemoglobin beta chain complex (HBB) −1.6
BI279605 Keratin complex 1, acidic, gene 19 (KRT1-19) −1.5
BI286012 Keratin complex 1, acidic, gene 18 (KRT1-18) −1.5
NM 033234 Hemoglobin beta chain complex (HBB) −1.4
X05080 Hemoglobin beta chain complex (HBB) −1.4
BI286387 Strong similarity to protein: SMALL PROLINE-RICH PROTEIN 1 (SPRR1) −1.3
AI179404 Hemoglobin, alpha 1 (HBA1) −1.3
AI071148 Transcribed sequences −1.1
AI179404 Hemoglobin, alpha 1 (HBA1) −1.1
Accession Title Day 5
NM 031055 Matrix metalloproteinase 9 (gelatinase B, 92 kD type IV collagenase) (MMP9) −2.8
AJ249701 RT1 class Ib gene (RT1AW2) −2.6
U18772 Neuronal pentraxin 1 (NPTX1) −2.4
NM 130744 Stellate cell activation associated protein (STAAP) −2.3
NM 022676 Protein phosphatase 1, regulatory (inhibitor) subunit 1A (PPP1R1A) −2.2
BI274408 Transcribed sequences −2.0
BF396602 Rattus norvegicus mRNA for putative secreted frizzled related protein (SFRP2 gene) −1.7
NM 012733 Retinol-binding protein 1 (RBP1) −1.7
NM 012593 Kallikrein 1 (KLK1) −1.6
BF281337 Keratin 8 (KRT8) −1.6
Accession Title Day 2
NM 013128 Carboxypeptidase E (CPE) −3.2
BF396602 Secreted frizzled related protein (sfrp2 gene) −2.6
NM 031055 Matrix metalloproteinase 9 (gelatinase B, 92 kD type IV collagenase) (MMP9) −2.4
NM 031009 Angiotensin II type-1 receptor (AGTR1) −2.3
BI282755 Transcribed sequences −2.2
BI274335 Weak similarity to protein ref tumor endothelial marker 1 precursor (Mus musculus) −2.1
NM 130744 Stellate cell activation associated protein (STAAP) −2.0
AI145313 Thymus cell surface antigen (THY1) −2.0
U18772 Neuronal pentraxin 1 (NPTX1) −1.9
NM 012862 Matrix Gla protein −1.8
aColumns show the mean change in gene expression expressed as signal log ratio (SLR) with an SLR of 0.6, 1.0, 2.0, and 4.0, corresponding to fold changes in gene
expression of 1.5, 2, 4, and 16, respectively.
at which time there is an early increase in mesangial cell
proliferation [15]. In contrast to Figure 4, Figure 6 re-
flects genes with a more gradual pattern of expression,
while finally Figure 7 considers those genes with a bipha-
sic response, with increased expression at both days 5 and
day 14.
Genes with exclusive expression at day 5 include
PDGF-A and PDGF-B, TGF-b1 and 2, and members of
the cyclin and S100 protein families (Fig. 4, primary clus-
ters A, B, and F). With secondary cluster analysis, these
genes realigned beside genes involved in signal trans-
duction, actin cytoskeletal organization, transcription
factors, and extracellular matrix genes (Fig. 4, secondary
clusters A, B, and F).
Proliferative genes that were almost exclusively ex-
pressed early include interleukin-6 receptor (IL-6R),
insulin-like growth factor-1 (IGF-1), and retinoblastoma-
1 (Fig. 5, primary cluster E). IL-6, a multifunctional cy-
tokine that regulates immune responses as well as acute
phase reactions, binds to its receptor, IL-6R, thereby ac-
tivating tyrosine kinases of the Janus kinase (JAK) family
and leading to signal transduction to the cytosol or nu-
cleus. Hemopoietic cell kinase (HCK), which shares the
same pattern of gene expression in this model (Fig. 5,
secondary cluster E1) is a protein tyrosine kinase that is
predominantly expressed in hemopoietic cells, and has
been shown to be activated by IL-6R in vitro [16].
Although Bcl2-like 1 (BCL2L1) and Bcl2-related pro-
tein A1 (BCL2A1) were not included in the original list
of proliferative genes, both of these mRNA transcripts
were identified with secondary cluster analysis (Fig. 5,
secondary clusters E1 and E3). Both of these genes are
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Fig. 3. Global changes in gene expression within major functional families of secondary level cluster analysis. Average linkage unsupervised
hierarchic analysis of all annotated genes of the Affymetrix rae230A microarray with an robust multichip analysis (RMA) signal log ratio (SLR) of
≤ −0.5 and/or ≥ +0.5 resulting in 2422 mRNA transcripts. There is a subtle change in the character of genes between day 5 and day 14: At day 5
there is mesangial cell injury and proliferation and consequently there is a greater number of genes involved in immune response and cell structure
perturbed than at day 14. Contrastingly, at day 14 there is repair and resolution of injury and thus genes involved in metabolism, cell communication,
and development dominate.
members of the BCL2 protein family and are therefore
involved in regulation of apoptosis [17]. It is notewor-
thy that BCL2L1, which closely aligns beside IL-6R has
been shown to be induced by IL-6 in B cells undergo-
ing apoptosis in vitro [18]. The observation in this model
of mesangial proliferative glomeulonephritis that expres-
sion of these apoptotic genes coincides with maximal
mesangial cell proliferation is consistent with previous
studies on this model [abstract; Baker et al, JCI 94:2105,
1994).
Genes with a biphasic response include B-cell translo-
cation gene 1 (BTG1), PDGF-A, and epithelial mem-
brane protein 1. BTG1 is an antiproliferative gene that
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
Fig. 2. Unsupervised hierarchic cluster analysis of 239 genes that encode cell growth and proliferation (primary level cluster analysis). Using Onto-
Compare and Gene Ontology, mRNA transcripts encoding proteins for cell proliferation and growth were selected for primary cluster analysis.
The major pattern of gene expression identified was over expression of proliferative genes at day 5 at which time point there is maximal mesangial
cell proliferation (primary clusters A to F). Within this cohort were smaller clusters of genes that that were exclusively up-regulated at day 5
(Primary clusters A, B, and F), genes that were up-regulated early in the disease model (primary clusters D and E), which is noteworthy as at 2 days
postinjection of anti-Thy antibody there is mesangiolysis that is quickly followed by mesangial cell proliferation which peaks at day 5 and finally a
cluster of genes that demonstrated a biphasic response of increased expression at both day 5 and day 14 (primary cluster C), at day 14 mesangial cell
number is returning toward normal, interestingly, the same biphasic pattern of change in days 5 and 14 was seen in down-regulated genes (primary
cluster J). For those genes with maximal perturbation at day 14, genes were either overexpressed or underexpressed (primary clusters G, H, I,
and K).
aligned beside RhoB gene with secondary cluster analysis
(Fig. 7, secondary cluster C3). This is an intriguing find-
ing as RhoB, a guanosine triphosphatase (GTPase) that
belongs to ras gene superfamily also has antiproliferative
effects and has been shown to inhibit cell proliferation in
various human cancer cells [19]. Experimentally RhoB is
induced by PDGF in rat fibroblasts in vitro which is no-
table as PDGF-A shares the same pattern of expression
in this model of anti-Thy1 nephritis [20].
As already stated in this model of anti-Thy1 nephritis,
day 14 is characterized by resolution of mesangial cell and
glomerular injury, with mesangial cell number returning
toward normal (Fig. 1A) [15]. Only a small number of
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Fig. 4. Secondary level cluster analysis. The major patterns of gene expression identified by primary cluster acted as bioinformatic bait to identify
other molecules, not previously reported as proliferative genes, but that shared similar patterns of expression and therefore could be potential novel
modulators of mesangial proliferative glomerulonephritis.
proliferative genes displayed exclusive expression at this
stage (Fig. 8, primary cluster G). Included within this co-
hort were IGFs, members of the cyclin family, and TGF-b
receptor 2 (TGF-bR2). With secondary baited cluster
analysis, genes that shared this pattern of expression in-
cluded the transcription factors: transcription factor 8
(TCF8) (Fig. 8, secondary cluster G1), forkhead box O1A
(Fig. 8, secondary cluster G3), GATA binding protein-2
(GATA2), and transcription factor upstream binding fac-
tor (UBF) (Fig. 8, secondary cluster G4).
Figures 9 and 10 examine those genes that were down-
regulated. Decreased mRNA expression demonstrated
two patterns; genes that were expressed early but grad-
ually expression fell off as glomerular recovery began
(Fig. 9), including CTGF and VEGF, and genes that
demonstrated a biphasic response with decreased expres-
sion at the day 5 and day 14 (Fig. 10). With secondary
cluster analysis, a number of negative regulators of cell
cycle shared these patterns of gene expression, including
Wilm’s tumor-1 and neuroblastoma-1.
Expression of genes identified in anti-Thy1 nephritis
in vivo during PDGF stimulated mesangial cell
proliferation in vitro
As outlined above, using primary and secondary baited
cluster analysis, a panel of genes with maximal dysregu-
lation at day 5 in anti-Thy1 nephritis were identified. As
day 5 corresponds to the time at which mesangial cell
proliferation peaks, we next examined the expression of
these genes in an in vitro model of mesangial cell pro-
liferation. Assessing the expression level of these genes
identified in anti-Thy1 nephritis in vivo during mesangial
cell proliferation in vitro thereby explores the molecular
mechanisms of mesangial cell proliferation.
Analysis revealed a cohort of proliferative genes un-
dergoing similar patterns of response in vivo and in
vitro that included TGF-b2, BCL21, and cyclin B1
(Table 3). In addition, genes identified global secondary
level baited cluster analysis in vivo demonstrated simi-
lar response during mesangial cell proliferation in vitro
(Table 3).
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Fig. 5. Secondary level cluster analysis. The major patterns of gene expression identified by primary cluster acted as bioinformatic bait to identify
other molecules, not previously reported as proliferative genes, but that shared similar patterns of expression and therefore could be potential novel
modulators of mesangial proliferative glomerulonephritis.
Validation of microarray findings with RT-PCR
To validate our model and to verify the expression pat-
terns obtained from the microarrays, we investigated the
expression of a number of key genes using quantitative
real-time PCR. As microarray experiments, including this
study, result in vast data sets, we limited RT-PCR to RNA
extracted from rat glomeruli on day 5 postadministration
of anti-Thy1 antibody. At day 5, there is peak cell prolif-
eration and it is the expression profiles around this time
point that were the major focus of this study.
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Fig. 6. Secondary level cluster analysis. The major patterns of gene expression identified by primary cluster acted as bioinformatic bait to identify
other molecules, not previously reported as proliferative genes, but that shared similar patterns of expression and therefore could be potential novel
modulators of mesangial proliferative glomerulonephritis.
The association of VEGF-C, PDGF, CTGF, and TGF-
b with mesangial cell proliferation has been extensively
documented, validation of our system focused on the
expression of these genes at day 5 postinjection of anti-
Thy1 antibody (Table 4) [15]. In all cases, mRNA tran-
scripts found to be significantly up-regulated at day 5
compared to control by microarray experiments demon-
strated similar changes by RT-PCR (Table 4): For exam-
ple, up-regulation of PDGF was determined to be 2.4-fold
change by microarray analysis and 2.62-fold compared to
respective control at day 5 post-anti-Thy1 antibody injec-
tion by RT-PCR (Table 4).
In this study, we also used gene expression patterns
identified by primary focused cluster analysis as bioin-
formatic bait to identify novel families of genes such as
the S100 family. Therefore, we also examined the mRNA
expression of these genes at day 5 postinjection of anti-
Thy1 antibody with real-time PCR (Table 4). Once again
the patterns of expression were consistent in microarray
and RT-PCR (Table 4). At day 5 enigma demonstrated
a fourfold increase in expression by microarray analysis
and a 2.62-fold change by RT-PCR compared to control.
Similarly, for S100A4 there was a marked increased in
expression at day 5, a finding that was consistent with the
two techniques (Table 4).
DISCUSSION
The anti-Thy1 nephritis is an acute and self-limited
model of mesangial proliferative glomerulonephritis that
is characterized by mesangiolysis with subsequent mesan-
gial cell proliferation and matrix expansion and ulti-
mately resolution of injury (Fig. 1A) [15]. In the present
study, microarray analysis was used to monitor serial
changes in the renal transcriptome during the evolution of
mesangial proliferative glomerulonephritis. As so much
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Fig. 7. Secondary level cluster analysis. The major patterns of gene expression identified by primary cluster acted as bioinformatic bait to identify
other molecules, not previously reported as proliferative genes, but that shared similar patterns of expression and therefore could be potential novel
modulators of mesangial proliferative glomerulonephritis.
2554 Sadlier et al: Gene expression in anti-Thy1 nephritis
CT
RL
DA
Y 
2
DA
Y 
5
DA
Y 
7
DA
Y 
14
Secondary cluster G1
CT
RL
DA
Y 
2
DA
Y 
5
DA
Y 
7
DA
Y 
14
Primary cluster G
CT
RL
DA
Y 
2
DA
Y 
5
DA
Y 
7
DA
Y 
14
Secondary cluster G2
CT
RL
DA
Y 
2
DA
Y 
5
DA
Y 
7
DA
Y 
14
Secondary cluster G4
CT
RL
DA
Y 
2
DA
Y 
5
DA
Y 
7
DA
Y 
14
Secondary cluster G3
Cyclin L
ATP-binding cassette, sub-family C (CFTR/MRP), member 9
Zinc finger protein 386 (Kruppel-like)
Carcinoembryonic antigen-related cell adhesion molecule 1
A disintegrin and metalloproteinase domain (ADAM) 15 (metargidin)
Transcription factor 8
Unconventional myosin Myr2 I heavy chain
Endothelial PAS domain protein 1
Cytochrome P450 4F5
Insulin-Like Growth Factor-Binding Protein 5
Kruppel-Like Factor 4 (Gut)
Pleiotrophin (Heparine Binding Factor, Hbnf, In The Mouse)
Carcinoembryonic Antigen-Related Cell Adhesion Molecule 1
Cyclin L
Insulin-Like Growth Factor-Binding Protein 5
Inhibitor of DNA Binding 1, Helix-Loop-Helix Protein
Dyskeratosis Congenita 1, Dyskerin
retinoblastoma-like 2
Transforming Growth Factor, Beta Receptor 2
Cyclin-Dependent Kinase Inhibitor 1A
Phosphatidate phosphohydrolase Type 2a
Cyclin D2
Neural cell adhesion molecule 1
Camo-requlated guanine uncleotide exhange factor I
Thyroid hormone receptor alpha
Calpain 5
DNA-damage inducible transcript 3
Solute carrier family 9 (sodium/hydrogen exchanger)
Diacylglycerol kinase, alpha (80 kda)
Hypothetical protein
Dyskeratosis congenita-1, dyskerin
UDP-N-acetylalucosamine-2-epimerase/N-acetylmannosamine kinase
Transcription factor UBF
Thrombomodulin
Cyclin D2
Requlator of G-protein signalling 19
Calcium/calmodulin-dependent protein kinase (cam kinase) II gammaNuclear protein 1
GATA binding protein 2
Ly6-C antigen gene
Kruppel−like factor 4 (gut)
Forkhead box 01A (rhabdomyosarcoma)
Calcium-independent alpha-latrotoxin receptor
Solute carrier family 6, member 6
Nesprin−1
Ctrl D2 D5 D7 D14
Nitric oxide synthase 3, endothelial cell
Cholinergic receptor, muscarinic 3
Thrombomodulin
Phosphatidate phosphohydrolase type 2a
Synaptic vesicle glycoprotein 2 b
Fig. 8. Secondary level cluster analysis. The major patterns of gene expression identified by primary cluster acted as bioinformatic bait to identify
other molecules, not previously reported as proliferative genes, but that shared similar patterns of expression and therefore could be potential novel
modulators of mesangial proliferative glomerulonephritis.
data is produced by microarray experiments, it can be
difficult to interpret the results; therefore, rather than fo-
cus on the expression of individual genes, we chose to
examine the expression profiles of all genes involved in
proliferation initially and then subsequently to use these
expression profiles to interrogate the renal transcriptome
as a whole (Figs. 1 to 10) [21].
During the evolution of mesangial proliferative
glomerulonephritis microarray analysis identified two
major peaks of gene expression; the initial peak corre-
sponded to maximal mesangial proliferation and matrix
expansion at day 5 and a second later peak at day 14 when
there was resolution of injury (Fig. 1C). Closer scrutiny
of these two peaks identifies a marked difference in gene
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Fig. 9. Secondary level cluster analysis. The major patterns of gene expression identified by primary cluster acted as bioinformatic bait to identify
other molecules, not previously reported as proliferative genes, but that shared similar patterns of expression and therefore could be potential novel
modulators of mesangial proliferative glomerulonephritis.
expression with a dominance of genes that encoded ma-
trix proteins and modulators of matrix turnover found
at day 5, while at day 14 there were a large number
of transcription factors expressed (Fig. 1D). With sec-
ondary baited cluster analysis, a technique that identifies
genes that share common expression patterns, prolifera-
tive genes were aligned to extracellular matrix genes at
day 5 (Fig. 4, secondary clusters A1, B2, and F1) and tran-
scription factors at day 14 (Fig. 8, secondary cluster G1
to G4).
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Fig. 10. Secondary level cluster analysis. The major patterns of gene expression identified by primary cluster acted as bioinformatic bait to identify
other molecules, not previously reported as proliferative genes, but that shared similar patterns of expression and therefore could be potential novel
modulators of mesangial proliferative glomerulonephritis.
Fibronectin (FN1), a glycoprotein that is involved in
cell migration, proliferation, and matrix formation dur-
ing tissue injury, also exhibited this pattern of increased
mRNA expression at the time of maximal mesangial
proliferation followed by a decline in expression with
resolution of injury (Fig. 4, secondary cluster B2). The
same expression profile in this model of anti-Thy1 nephri-
tis has been previously been shown in vivo [22]. Other
genes that encode extracellular matrix and that shared
this pattern of expression included fibrillin-1, procolla-
gen, type 1, and dermatopontin (Fig. 4, secondary cluster
B2).
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Table 3. Some genes identified by microarray analysis of anti-Thy1 nephritis in vivo undergoing similar changes during in vitro mesangial cell
proliferation
Accession Gene SLRa Gene Ontology
Expression during in vitro mesangial cell proliferation of proliferative genes identified during anti-Thy1.1 mesangioproliferative
glomerulonephritis in vivo
BF061658 Transforming growth factor, beta 2 (TGFB2) 1.4 Proliferation
Signal transduction
K03199.1 Tumor protein 53 (Li-Fraumeni syndrome) (TP53) 1.0 Proliferation
Transcription
NM 005504.1 Branched chain aminotransferase 1, cytosolic (BCAT1) 0.8 Proliferation
Metabolism
NM 001191.1 BCL2-like 1 (BCL2L1) 0.7 Proliferation
Anti-apoptosis
AI633566 Microtubule-associated protein, RP/EB family, member 1 (MAPRE1) 0.6 Proliferation
Cell-cycle regulation
NM 001168.1 Baculoviral IAP repeat-containing 5 (Survivin) (BIRC5) 0.6 Proliferation
Anti-apoptosis
BE407516 Cyclin B1 (CCNB1) 0.6 Proliferation
Cell-cycle regulation
Expression during in vitro mesangial cell proliferation of proliferative genes identified by second level cluster analysis during anti-Thy1.1
mesangioproliferative glomerulonephritis in vivo
Up-regulated genes
U28936.1 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 1.3 Intracellular signaling cascade
activation protein, epsilon polypeptide (YWHAE)
AF109196.1 Chloride intracellular channel 4 (CLIC4) 1.3 Chloride transport
U28964.1 Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase 1.1 Intracellular signaling cascade
activation protein, zeta polypeptide (YWHAZ)
BC005147.1 FK506 binding protein 1A, 12 kD (FKBP1A) 1.1 Protein folding
AA580004 ADP-ribosylation factor 1 (ARF1) 1.1 Intracellular protein transport
NM 006815.1 Coated vesicle membrane protein (RNP24) 1.0 Intracellular protein transport
NM 001067.1 Topoisomerase (DNA) II alpha 170 kD (TOP2A) 1.0 DNA metabolism
D88357.1 Cell division cycle 2, G1 to S and G2 to M (CDC2) 1.0 Cell cycle—mitosis
NM 003358.1 UDP-glucose ceramide glucosyltransferase 1.0 Metabolism
AJ251595.1 CD44 antigen (homing function and Indian blood group system) (CD44) 0.9 Cell-cell adhesion
NM 003483.2 High mobility group AT-hook 2 (HMGA2) 0.9 Development
AA679988 Polypyrimidine tract binding protein 1 (PTBP1) 0.9 RNA binding protein
NM 004508.1 Isopentenyl-diphosphate delta isomerase (IDI1) 0.8 Metabolism
U12170.1 Transcription factor 8 (represses interleukin 2 expression) (TCF8) 0.7 Transcription
L18887.1 Calnexin (CANX) 0.7 Protein secretion
NM 014456.1 Programmed cell death 4 (neoplastic transformation inhibitor) (PDCD4) 0.7 Apoptosis
AW206786 Enigma (LIM domain protein) (ENIGMA) 0.7 Development
U81380.2 Interleukin 13 receptor, alpha 1 (IL13RA1) 0.7 Signal transduction
U16120.1 Solute carrier family 6 (neurotransmitter transporter, taurine), member 6 (SLC6A6) 0.7 Amino acid metabolism
AW163148 Myristoylated alanine-rich protein kinase C substrate (MARCKS) 0.6 Cell motility
Y15916.1 Collagen, type I, alpha 1 (COL1A1) 0.6 Skeletal development
AL518627 3-hydroxy-3-methylglutaryl-Coenzyme A reductase (HMGCR) 0.6 Development
BF971587 Beta 5-tubulin (OK/SW-cl.56) 0.6 Natural killer cell
NM 014467.1 Sushi-repeat protein (SRPUL) 0.6 Electron transport
AI038068 Dynactin 4 (MGC3248) 0.6 Development
NM 001430.1 Endothelial PAS domain protein 1 (EPAS1) 0.6 Transcription
AB007899.1 Neural precursor cell expressed, developmentally down-regulated 4-like (NEDD4L) 0.6 Development
NM 002881.1 V-ral simian leukemia viral oncogene homolog B (RALB) 0.6 Signal transduction
aColumns show the mean change in gene expression expressed as signal log ratio (SLR) with an SLR of 0.6, 1.0, 2.0, and 4.0, corresponding to fold changes in gene
expression of 1.5, 2, 4, and 16, respectively.
With secondary cluster analysis, mRNA transcripts en-
coding proteins involved in cell proliferation and almost
exclusively expressed at day 14 aligned beside a num-
ber of transcription factors (Fig. 8, secondary clusters
G1 to G4). Among these were TCF8 and FOXO1A.
TCF8 is a transcription factor that is involved in cell pro-
liferation through its ability to regulate TGF-b . TCF8
binds to transcriptional coactivators that lead to activa-
tion of transcription of specific target genes in vitro and
in vivo [12, 23, 24]. Similarly, FOXO1A is also involved
in cell proliferation; however, unlike TCF8, increased
expression of FOXO1A is associated with cell cycle
inhibition.
Identification of PDGF pathway members and
PDGF-driven genes by primary proliferation–focused
cluster analysis
PGDF is a key player in mesangial cell proliferation
and matrix accumulation [15]. It is a potent mesangial
cell mitogen in vitro and although both macrophages and
platelets produce PDGF the principal source is believed
to be from the mesangial cell itself [15]. Previous work
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Table 4. Validation of the expression patterns obtained from by
microarrays with quantitative real-time reverse
transcription-polymerase chain reaction (RT-PCR)
Gene Microarray analysis RT-PCR
Expression during of proliferative genes identified during anti-Thy1.1
mesangioproliferative glomerulonephritis in vivo
PDGF 2.4 (SEM ± 0.3) 2.62 (P < 0.003)
VEGF-C 3.0 (SEM ± 0.3) 2.41 (P < 0.004)
CTGF 2.2 (SEM ± 0.3) 1.13 (P < 0.258)
TGF-b 3.0 (SEM ± 0.3) 1.70 (P < 0.002)
Moesin 3.0 (SEM ± 0.3) 1.74 (P < 0.012)
Expression during anti-Thy1.1 mesangioproliferative
glomerulonephritis in vivo identified by second level
cluster analysis
ENIGMA 4 (SEM ± 0.3) 2.85 (P < 0.011)
S100A4 8.0 (SEM ± 0.3) 11.01 (P < 0.000)
S100A6 3.0 (SEM ± 0.3) 1.94 (P < 0.004)
S100A9 3.0 (SEM ± 0.3) 2.88 (P < 0.000)
S100A10 3.0 (SEM ± 0.3) 1.82 (P < 0.004)
Abbreviations are: PDGF, platelet-derived growth factor; VEGF-C, vascular
endothelial growth factor-C; CTGF, connective tissue growth factor; TGF-b ,
transforming growth factor-b . Columns show the mean change in gene expression
from separate experiments expressed as fold changes in gene expression of 1.5,
2, 4. and 16, respectively.
on this model identified increased expression of both
PDGF-A and PDGF-B chain following injection of anti-
Thy1 antibody and in particular there was up-regulation
of mesangial cell PDGF-b receptor mRNA, a finding that
was reproduced in this study, where both PDGF-A chain
and PDGF-b receptor were significantly increased [15,
25, 26]. PDGF-A chain demonstrated a biphasic expres-
sion with two peaks of increased expression at days 5 and
14 (Fig. 2, cluster C), while there was a steady increase
PDGF-b receptor expression peaking at day 14 (Fig. 2,
cluster B). As with previous work PDGF-a receptor was
not altered. In constellation these findings support the
evidence that mesangial cell proliferation is modulated
by PDGF and its receptors in an autocrine fashion [15,
25, 26].
Consistent with the proliferation was an increase in
various cell cycle regulatory proteins, including cyclin B1,
cyclin G1, cyclin-dependent kinases 4 and 7 (CDK4 and
CDK7). Previously there had been little evidence for in-
volvement of cyclin B1 (CCNB1) in mesangial cell prolif-
eration [27]. Cyclin B1 is down-regulated by mechanical
stretch in podocytes [28], contrasting with this study in
which this gene was induced. CDK4, cyclin D1, and
retinoblastoma (RB) were also expressed in this model
of mesangial cell proliferation (Fig. 3), consistent with
studies showing involvement of activation of the cyclin-
dependent kinases and early cyclins in this model [27].
With secondary level cluster analysis PDGF-A chain
aligned beside tumor necrosis factor (TNF)–induced
protein 6 (TNFAIP6), Arg/Abl-interacting protein 2
(ARGBP2), and protein tyrosine kinase (PTK2) (Fig. 7,
Secondary cluster C3). The protein encoded by TNFAIP6
is a secretory protein that is involved in extracellular ma-
trix stability and cell migration. The expression of this
gene can be induced by TNF-a and IL-1 [29]. ARGBP2
is widely expressed in human tissues and is a binding pro-
tein for the nonreceptor protein tyrosine kinases c-Abl
and c-Arg [30]. In epithelial cells, ARGBP2 is located
in stress fibers and the nucleus where it functions as an
adaptor protein and is involved in signal transduction and
actin cytoskeletal organization [31]. It is noteworthy that
both c-Abl and c-Arg are activated and form complexes
with proteins in the PDGF signaling pathway [41]. PTK2
is a cytoplasmic protein tyrosine kinase, which concen-
trates, in the focal adhesions that form between cells and
has been implicated in signaling pathways involved in
cell motility, proliferation and apoptosis. PDGF is known
to increase the phosphotyrosine content of PTK2 in cul-
tured cells in vitro, thereby activating PTK2 [32]. Zent
et al [33] reported increased tyrosine phosphorylation of
PTK2 in mesangial cells grown in a three-dimensional
collagen gel in vitro.
Identification of the TGF-b sclerotic fibrotic pathway
within primary cluster analysis
Clustering alongside PDGF-Rb were members of the
TGF-b , the collagens, type 5 alpha 2 (COLA2) and
type 18 alpha 1 (COL18A1), as well as laminin and fi-
bronectin [15, 34]. The TGF-b superfamily of proteins in-
fluence cell proliferation, apoptosis, matrix turnover, and
fibrosis through their effects on the release and action
of other cytokines. An increase was observed in TGF-
b1–induced transcript-1, bone morphogenetic protein 2
(BMP2), TGF-b2, and TGF-b3, along with other mem-
bers of the TGF-b-pathway. TGF-b is thought to medi-
ate some of its effects via CTGF and similarly we found
that CTGF mRNA expression was increased by day 2,
continued to climb and peaked at day 7 (Fig. 2, primary
cluster I). By day 14 when mesangiolysis, inflammation,
and proliferation have mostly resolved there was a dra-
matic fall off in the expression of CTGF mRNA, findings
that are in keeping with previous work [35].
TGF-b also is known to stimulate tissue inhibitor of
metalloproteinase-1 (TIMP-1) and signal transducer and
activator of transcription 1 (STAT1), and these showed
increased expression at day 5 (Fig. 2, primary clusters
A, B, and F), findings consistent with previous reports in
models of mesangial cell proliferative glomerulonephritis
in vitro and in vivo [15, 34, 36, 37]. STAT1 is known to
regulate TIMP-1 expression in mesangial cells in vitro
[38].
With secondary level clustering BMP2 aligned to extra-
cellular matrix proteins or modulators of matrix turnover,
including COL5A1, COL1A1, gravin (AKAP12), and
follistatin-like 1 (FLT1) (Fig. 4, secondary cluster B3).
BMP2 belongs to a family of growth and differentiation
factors, which play an important role in the development
of many organs but particularly the kidney [39]. BMP2
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has been shown to inhibit PDGF-induced DNA synthesis
in mesangial cells in vitro by inhibiting mitogen-activated
protein kinase (MAPK)–mediated transcription [39].
Identification of cytoskeletal changes with cluster
analysis in anti-Thy1 nephritis
Increase in mesangial cell population occurs soon af-
ter injection of anti-Thy1 antibody and is due to immi-
gration and proliferation of mesangial cells that peaks at
day 5 and is accompanied by mesangial matrix expan-
sion [15]. TGF-b2, TIMP-1, and STAT1 are prolifera-
tive genes that clustered closely both with primary and
secondary cluster analysis (Fig. 4, primary cluster F and
secondary cluster F1). With secondary cluster analysis
these genes also aligned beside actin-b (ACTB), cofilin-
1 (CFL1), myotrophin (V-1 protein) and moesin (Msn),
all genes involved in cyoskeletal function. ACTB was
originally described as a nonmuscle cytoskeletal actin ex-
pressed in a variety of tissues and organs and involved
in axon regrowth following injury [40]. A role in kidney
disease has not been described previously. CFL1 is an
actin-modulating protein, also found in a variety of cell
types, that is a key modulator of cytoskeletal integrity.
A recent study demonstrated increased CFL1 expression
and activation in mesangial cells treated with mycophe-
nolic acid causing cytoskeletal disruption in vitro [41].
In a separate study by Malmstrom et al [42] TGF-b in-
duced cofilin expression in fibroblasts along with other
cytoskeletal proteins as cells differentiated into its acti-
vated form. Moesin is a cytoskeletal protein that is crucial
for cell-cell adhesion [43]. Hugo et al [43] demonstrated a
marked increased expression of moesin in mesangial pro-
liferative glomerulonephritis (anti-Thy1 model). Similar
to this study expression of moesin correlated with mesan-
gial cell proliferaton and by day 14 when there was reso-
lution of the injury there was a notable decline in moesin
expression [43].
Identification of the S100 protein family
A new finding was the observation that four members
of the S100 protein family, S100A4, S100A6, S100A9,
and S100A10, exhibited maximal expression at day 5
(Fig. 3, primary clusters A and C). S100 proteins are
a family of small highly homologous calcium binding
proteins that are widely expressed in normal tissue and
function in a variety of cellular processes, including cell
proliferation and differentiation [44]. In a recent study
of human renal biopsy samples Robertson et al [45]
demonstrated increased expression of S100A4 in the
tubular epithelium in acute transplant rejection. The in-
creased S100A4 occurred in the setting of epithelial-to-
mesenchyme transdifferentiation (EMT), which is known
to play an important role in the progression of renal fi-
brosis [45]. Although the function of S100A6 (calcyclin)
is not fully understood, it is widely expressed in normal
kidney and has been shown to be increased following
renal ischemic injury in vivo [46]. Less is known about
S100A10 (also called annexin II) although it has been
shown to be expressed in renal cell carcinoma in vitro
[47]. S100AA9, also known as calgranulin B, was signifi-
cantly up-regulated at both days 5 and 14 which is inter-
esting given that S100A9 is expressed by macrophages
in acutely inflamed tissues. In vitro studies have shown
S100A9 as a surrogate marker for acute antibody medi-
ated rejection in renal transplantation [48].
With secondary level cluster analysis this family of
genes aligned to a variety of complementary genes, in-
cluding extracellular matrix constituents, growth fac-
tors, and other cytokines (Fig. 4, secondary clusters A1
and A2) (Fig. 5, secondary cluster C2). S100A4 closely
aligned to hypoxia-inducible factor-1a (HIF-1a), en-
dothelial cell–specific molecule 1 and defender against
death 1 (Fig. 4, secondary cluster A1). HIF-1a is a tran-
scription factor that has a key role in cellular response
to hypoxia, including the regulation of genes involved in
energy metabolism, angiogenesis, and apoptosis [49]. In
a recent study by Leonard et al [50], microarray analy-
sis of human proximal tubular epithelial cells exposed to
hypoxia in vitro identified a distinct cohort of 48 genes
that shared a similar hypoxia-dependent expression pro-
file. Both HIF-1a and PDGF-b were part of this cohort
and had closely related expression profiles [50].
There is now considerable evidence to suggest that re-
capitulation of developmental genes occurs in adult dis-
ease states [51]. In this regard S100A9 clustered with a
number of proliferative genes with an additional develop-
mental function: FMS-related tyrosine kinase 1 (FLT1),
C-terminal binding protein 2 (CTBP2), epithelial mem-
brane protein 1 (EMP1), and peripheral myelin protein
22 (PMP22) (Fig. 2, primary cluster C) [52–55]. With sec-
ondary cluster analysis S100A9 aligns to STAT3. STAT3
encodes a protein that is a member of the STAT family
and acts as a transcription activator. Significantly, Kalech-
man et al [56] recently identified STAT3 as playing a piv-
otal role in IL-10–induced mesangial cell proliferation in
vitro and in vivo.
Identification of enigma in anti-Thy1 nephritis in vivo and
during PDGF-stimulated mesangial cell proliferation in
vitro and modulation by lipoxin
Examination of the expression level of several genes
perturbed in anti-Thy1 nephritis in vivo was also found
to be similarly perturbed during mesangial cell prolifer-
ation in vitro. Enigma clustered alongside STAT1 and
phopholipase A2 with global secondary level baited clus-
ter analysis (Fig. 4, secondary cluster F2). Additionally, it
was significantly perturbed during mesangial cell prolifer-
ation in vitro (Table 3). Enigma is a member of a family of
proteins consisting of conserved PDZ and LIM domains.
LIM domains are highly conserved cysteine-rich double
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zinc fingers involved in protein-protein interactions. The
LIM domains of enigma bind to protein kinases, while the
PDZ domain binds to actin filaments. The interaction of
LIM domains with specific protein partners influences cy-
toskeleton organization, cell lineage specification, organ
development, and oncogenesis [57]. Enigma is involved
in signal transduction as well as the positive regulation of
osteoblast differentiation [58].
Interestingly, in further work done by us the effect
of lipoxin on mesangial cell proliferation in vitro was
studied [59]. Lipoxins are endogenously produced anti-
inflammatory eicosanoids that have anti-inflammatory
activity in glomerulonephritis, hypersensitivity, and
ischemia/reperfusion injury [60]. Lipoxin inhibits PDGF-
stimulated proliferation through modulation of PDGF-
Rb activation [3]. As expected, in our panel of established
proliferative genes (BMP2, cyclin D2, and TGF-b) and
novel modulators of mesangial proliferation (enigma and
moesin), PDGF-stimulated mesangial cell proliferation
was associated with similar patterns of gene expression in
vivo and in vitro while the administration of lipoxin and
resultant mesangial cell inhibition was associated with
a significant fall in the expression of these same genes
[59]. In the case of enigma, TGF-b2 and BMP2 there
was a dramatic decrease in their mRNA expression in
response to lipoxin administration. It is noteworthy that
these same genes exhibited peak expression at day 5 of
anti-Thy1 nephritis in vivo, the time at which there is peak
mesangial cell proliferation. In aggregate the finding of
increased expression of enigma, TGF-b2 and BMP2 dur-
ing mesangial cell proliferation both in vivo and in vitro in
conjunction with the inhibition by lipoxin in vitro further
emphasizes their role in mesangial cell proliferation.
CONCLUSION
Sequential proliferation-focused primary cluster anal-
ysis followed by baited global secondary cluster analysis
identified both established and novel gene networks. The
additional study of a representative sample of these genes
in vitro and their response to lipoxin confirms these genes
as potential contributors to mesangial cell dysfunction
in glomerular disease. Thus microarray analysis provides
the transcriptomic framework upon which to base fur-
ther pathway and molecule-specific interrogations of the
complex web of molecular events that subserve glomeru-
lar injury in disease. This study demonstrates the utility
of this approach to both confirm and discover genes in-
volved in glomerular disease.
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